ARTICLE | Clinical News
Calsed amrubicin: Final Phase II data
August 10, 2009 7:00 AM UTC
Final data from 72 evaluable patients sensitive to previous first-line platinum-based therapy in an open-label, U.S. Phase II trial, showed that amrubicin met the primary endpoint of a significantly h...